<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916951</url>
  </required_header>
  <id_info>
    <org_study_id>20-2877</org_study_id>
    <nct_id>NCT04916951</nct_id>
  </id_info>
  <brief_title>Oral Amoxicillin and Cephalexin PK/PD in Neonates</brief_title>
  <official_title>Oral Amoxicillin and Cephalexin Pharmacokinetics/Pharmacodynamics (PK/PD) in the Neonatal Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to figure out the best doses for two oral antibiotics (called&#xD;
      amoxicillin and cephalexin) when they are used to treat infections in newborns and young&#xD;
      infants. In order to do this, the study plans to enroll two groups of young infants who are&#xD;
      admitted to the Children's Hospital Colorado. In the first group, infants already receiving&#xD;
      one of these two antibiotics will be enrolled. Over a few days in the hospital, up to 5 blood&#xD;
      samples will be collected from each infant to measure how much of the drug is in their body&#xD;
      at different points in time after a dose. In the second group, infants who are already&#xD;
      receiving an IV antibiotic and who are eating normally or receiving oral medications will be&#xD;
      enrolled. These infants will receive one dose by mouth of either amoxicillin or cephalexin,&#xD;
      in addition to the IV antibiotic already being used to treat their infection. After the oral&#xD;
      antibiotic dose,blood will be drawn every few hours to measure how much of the drug is still&#xD;
      in their body. Blood levels of the antibiotics will be used to calculate how much and how&#xD;
      often both antibiotics would need to be given to treat a variety of infections that are&#xD;
      common in infants. The study will calculate if using a single blood level can predict whether&#xD;
      or not an infant might be at risk of the antibiotic not working well enough for them.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal's objective is to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of&#xD;
      enteral amoxicillin and cephalexin in neonates and young infants admitted to the hospital,&#xD;
      characterize age-stratified PK/PD parameters, and use these data to improve neonatal&#xD;
      antibiotic dosing strategies. This will involve developing and validating small-volume&#xD;
      sampling assays using dried blood spots. The study hypothesizes that there will be&#xD;
      significant inter-individual variation in amoxicillin and cephalexin PK/PD parameters in&#xD;
      neonates and that delayed absorption and elimination will lead to longer times to maximal&#xD;
      concentrations (Tmax) and prolonged half-lives (T1/2), most prominently in younger ages. In&#xD;
      addition, the study hypothesizes that high inter-individual variability will lead to&#xD;
      unacceptably low attainment of PK/PD efficacy targets using standard dosing regimens. To&#xD;
      address this low target attainment, the study will aim to incorporate therapeutic drug&#xD;
      monitoring (TDM), using a serum trough concentration, into this PD model to create a method&#xD;
      that more accurately identifies patients likely to succeed with oral (PO) dosing. Preliminary&#xD;
      physiologically based pharmacokinetic (PBPK) modeling and intestinal transporter genotyping&#xD;
      will also provide a foundation for future studies on the most important factors that lead to&#xD;
      interpatient variability in PK parameters. The neonatal population has much to gain from an&#xD;
      improved understanding of age-specific PK/PD, as well as more frequent, and earlier,&#xD;
      intravenous (IV) to PO transition of antibiotics. The specific aims of this study are to:&#xD;
&#xD;
      Specific Aim 1: Use a population PK approach to define PK parameters of enteral amoxicillin&#xD;
      and cephalexin in infants aged 0-60 days, stratified by age group. This will include building&#xD;
      preliminary physiologically based pharmacokinetic (PBPK) models for each drug.&#xD;
&#xD;
      Specific Aim 2: Develop and validate amoxicillin and cephalexin dried-blood spot assays.&#xD;
&#xD;
      Specific Aim 3: Perform PD modeling 3A: Perform PD modeling (including Monte Carlo&#xD;
      simulation) to evaluate the expected PK/PD target attainment of amoxicillin and cephalexin by&#xD;
      age group.&#xD;
&#xD;
      3B: Identify a minimum trough threshold needed to establish 95% target attainment.&#xD;
&#xD;
      Exploratory Aim: Correlate patient genotype for H(+)/peptide transporters (PEPT) 1 and 2 and&#xD;
      the organic-anion-transporting polypeptide (OATP) family of transporters with&#xD;
      patient-specific PK parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time above Minimum Inhibitory Concentration (T &gt; MIC)</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>As a surrogate of treatment efficacy for amoxicillin and cephalexin, the investigators will determine the time that free plasma concentrations (fT &gt; MIC) of amoxicillin and cephalexin remain above the minimum inhibitory concentration (MIC) of common neonatal pathogens. Monte Carlo simulation will be used to assess for the likelihood of fT &gt; MIC dosing goals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F) of amoxicillin and cephalexin</measure>
    <time_frame>Plasma drug concentrations obtained within 12 hours of a dose</time_frame>
    <description>In defining pharmacokinetic parameters for both amoxicillin and cephalexin, the investigators will assess the Clearance, or CL/F (L/h/kg), of both drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (V/F) of amoxicillin and cephalexin</measure>
    <time_frame>Plasma drug concentrations obtained within 12 hours of a dose</time_frame>
    <description>In defining pharmacokinetic parameters for both amoxicillin and cephalexin, the investigators will assess the Volume of Distribution, or V/F (L/kg), of both drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T1/2) of amoxicillin and cephalexin</measure>
    <time_frame>Plasma drug concentrations obtained within 12 hours of a dose</time_frame>
    <description>In defining pharmacokinetic parameters for both amoxicillin and cephalexin, the investigators will assess the half life, or T1/2 (hours), of both drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of amoxicillin and cephalexin</measure>
    <time_frame>Plasma drug concentrations obtained within 12 hours of a dose</time_frame>
    <description>In defining pharmacokinetic parameters for both amoxicillin and cephalexin, the investigators will assess the area under the curve, or AUC (h*mg/L), of both drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak serum drug concentration (Cmax) of amoxicillin and cephalexin</measure>
    <time_frame>Plasma drug concentrations obtained within 12 hours of a dose</time_frame>
    <description>In defining pharmacokinetic parameters for both amoxicillin and cephalexin, the investigators will assess the peak serum drug concentration, or Cmax (mg/L), of both drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum drug concentration (Cmin) of amoxicillin and cephalexin</measure>
    <time_frame>Plasma drug concentrations obtained within 12 hours of a dose</time_frame>
    <description>In defining pharmacokinetic parameters for both amoxicillin and cephalexin, the investigators will assess the minimum serum drug concentration, or Cmin (mg/L), of both drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximal drug concentration is achieved (Tmax) of amoxicillin and cephalexin</measure>
    <time_frame>Plasma drug concentrations obtained within 12 hours of a dose</time_frame>
    <description>In defining pharmacokinetic parameters for both amoxicillin and cephalexin, the investigators will assess the time at which maximal drug concentration is achieved, or Tmax (hours), of both drugs.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neonatal Infection</condition>
  <arm_group>
    <arm_group_label>Amoxicillin - standard-of-care dose</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Obtain amoxicillin plasma concentrations in patients already receiving amoxicillin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cephalexin - standard-of-care dose</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Obtain cephalexin plasma concentrations in patients already receiving cephalexin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin - study dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obtain amoxicillin plasma concentrations after a study-administered dose of amoxicillin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cephalexin - study dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obtain cephalexin plasma concentrations after a study-administered dose of cephalexin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>oral one-time dose of amoxicillin</description>
    <arm_group_label>Amoxicillin - study dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>oral one-time dose of cephalexin</description>
    <arm_group_label>Cephalexin - study dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to Children's Hospital Colorado derived from two groups:&#xD;
&#xD;
               -  Group 1-patients specifically receiving enteral amoxicillin (with or without&#xD;
                  clavulanate) or cephalexin for any clinical indication;&#xD;
&#xD;
               -  Group 2-patients receiving any IV antibiotic who are tolerating full enteral&#xD;
                  feeds and/or enteral medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Across both groups, exclusion criteria are: (1) weight &lt;2kg, (2) renal dysfunction,&#xD;
             including the use of any renal replacement therapy, (3) significant Î²-lactam allergy,&#xD;
             (4) GI disorders significantly impairing drug absorption, (5) use of external circuits&#xD;
             that would affect the study drug's volume of distribution (e.g. ECMO), and (6)&#xD;
             clinically significant anemia precluding study-related blood draws.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Haynes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado - Anschutz Medical Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

